Elan shares jump after FDA decision
Shares in Elan have rocketed 9% today after the company received a huge boost in the US for its plans for a new treatment for multiple sclerosis.
Elan today saw its Antegren drug designated for priority review and accelerated approval by the US Food and Drug Administration (FDA), sparking a surge in the company's share price.